Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
BioPharmaceutical
Report



- Mar 19, 2019
- 4 min
Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake


- Mar 12, 2019
- 5 min
Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval


- Mar 12, 2019
- 8 min
Shooting for the Universe


- Mar 12, 2019
- 5 min
Biosimilar Uptake Still Plagued by Interchangeability Hurdles


- Mar 12, 2019
- 5 min
Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments


- Mar 12, 2019
- 4 min
BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica


- Mar 12, 2019
- 6 min
Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations


- Mar 12, 2019
- 7 min
Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery


- Mar 12, 2019
- 5 min
Medical Device: Growing Cybersecurity Threat and Need for More Regulation


- Mar 12, 2019
- 5 min
Eisai’s Lenvima Should See FDA Approval in Hepatocellular Carcinoma (HCC)


- Mar 12, 2019
- 5 min
Western CAR-Ts face Chinese Development Hurdles Due to Regulatory Uncertainty


- Mar 12, 2019
- 5 min
Legislation to Force Payer Coverage of AbuseDeterrent Opioids Faces Resistance


- Mar 12, 2019
- 4 min
Roche’s GALLIUM Results Draw Skepticism about Changing Practice in First-Line Follicular Lymphoma


- Mar 12, 2019
- 5 min
Humira Biosimilar Unlikely to Reach the Market Before 2020